Medical device company Centinel Spine saw its Prodisc total disc replacement sales grow 56% in the ASC setting between 2022 and 2023.
Prodisc sales overall were up 55% from the year prior, at $70 million, according to the company's year-end financial results. Centinel focuses exclusively on treating cervical and lumbar spinal disease with its total disc replacement technology platform. Its growth in the ASC space signals an overall trend of spinal procedures shifting from the inpatient to the outpatient setting.
"The past decade has shown us that orthopedic and spine surgery (in the properly indicated patient) can be performed in a safer, more efficient and cost-saving manner compared to the traditional large hospital setting. This migration of surgeries to the ambulatory surgery centers and other outpatient centers have been fueled by the innovation of several enabling technologies. With ongoing financial stressors of large hospital systems and patients' concerns with hospitals, the ability to expand technologies to aid safe surgeries in outpatient settings will be paramount. Understanding how this all plays out in a landscape trying to become more value-based will be interesting to be a part of," Philip Louie, MD, a spine surgeon and medical director of research and academics at Virginia Mason Franciscan Health's Center for Neurosciences and Spine in Seattle, told Becker's.
While spine's transition to the ASC setting is still in its early stages, ASCs including Newport, Calif.-based DISC Surgery Center and Miami Spine Specialists have made major strides in the last three months, launching new spine technology and enrolling patients in new spine studies.